Efficacy of the oral JAK3/TEC inhibitor ritlecitinib (PF-06651600) in patients with alopecia areata over 48 weeks: Results from the ALLEGRO Phase 2b/3 randomized, double-blind, placebocontrolled trial
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined